Last reviewed · How we verify
Beta-Dihydroergocryptine (EPICRIPTINE)
Beta-Dihydroergocryptine (generic name: EPICRIPTINE) is a epicriptine drug. It is currently FDA-approved for Alzheimer's disease, Senile dementia.
At a glance
| Generic name | EPICRIPTINE |
|---|---|
| Drug class | epicriptine |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Alzheimer's disease
- Senile dementia
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Beta-Dihydroergocryptine CI brief — competitive landscape report
- Beta-Dihydroergocryptine updates RSS · CI watch RSS
Frequently asked questions about Beta-Dihydroergocryptine
What is Beta-Dihydroergocryptine?
Beta-Dihydroergocryptine (EPICRIPTINE) is a epicriptine drug, indicated for Alzheimer's disease, Senile dementia.
What is Beta-Dihydroergocryptine used for?
Beta-Dihydroergocryptine is indicated for Alzheimer's disease, Senile dementia.
What is the generic name of Beta-Dihydroergocryptine?
EPICRIPTINE is the generic (nonproprietary) name of Beta-Dihydroergocryptine.
What drug class is Beta-Dihydroergocryptine in?
Beta-Dihydroergocryptine belongs to the epicriptine class. See all epicriptine drugs at /class/epicriptine.
What development phase is Beta-Dihydroergocryptine in?
Beta-Dihydroergocryptine is FDA-approved (marketed).
Related
- Drug class: All epicriptine drugs
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Alzheimer's disease
- Indication: Drugs for Senile dementia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing